14th Annual Patient Recruitment and Retention Summit

23 - 24 February 2022 | Berlin / Online

PAST SPEAKERS

SEE THE PREVIOUS SPEAKERS & CASE STUDIES

Gunnar SCHROEFEL

Global Director Patient Advocacy

Kimberley KALLSEN

Head of Patient & Site Journey, Global Clinical Development & Operations

Oleksandr GORBENKO

Global Patient Centricity Director

Karin BLUMER

Director Global Patient Engagement

Marta Garcia MANRIQUE

R&D. Chief Patient Officer

CONFERENCE TOPICS 2022

LOOK AT THE TOPICS THAT WERE DISCUSSED

  • The diversification of the patient recruitment approaches as a tool for the research underperformance prevention
  • What is the role of decentralised clinical trial methods in the process of patient enrolment?
  • The cooperation between companies and patient organisations as a way to facilitate patient engagement
  • How to develop and apply the relevant Patients Focused Medicine Development (PFMD) guides to encourage patients to stay in the trial?
  • Ways to communicate and aid your patients: Support programmes, counselling sessions and patient communities
  • Benefits and challenges of virtual clinical trials: Exploiting technology for effective global reach
  • Coping with the new normal: Lessons to learn and changes to do for patient engagement and retention

Designed for

Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from banking industry involved in:

  • Patient Recruitment
  • Patient Retention
  • Clinical Trials
  • Clinical Study
  • Patient Centricity
  • Recruitment Programmes
  • Patient Engagement
  • Site & Patient Access
  • Trials Transparency
  • Feasibility & Recruitment
CASE STUDY / DAY 1

Patient-Relevant Clinical Trials: Early Patient Involvement in the Design of Development Programmes

Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.

  • Comparing the perspectives of industry, research and patients
  • What are best practices in involving patient representatives in clinical trial design?
  • What are key challenges, and how are they overcome?
  • Discussing the way to go to take patient involvement to the next level

Gunnar SCHROEFEL

Global Director Patient Advocacy

Kimberley KALLSEN

Head of Patient & Site Journey, Global Clinical Development & Operations

CASE STUDY / DAY 2

The Journey of Bringing the Voice of Patients and Sites into End-to-End Clinical Development

Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations. 

  • Examples for understanding the voice of patients and sites and bringing it into clinical development
  • The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
  • Challenges and future opportunities
CASE STUDY / DAY 2

Revolutions Need Evolution - How Cell and Gene Therapies Transform Patient Engagement

In 2017, the FDA approved the first-ever CAR-T cell therapy for a rare hematologic malignancy. This approval was considered a scientific revolution by many. Since then, several other gene therapies entered the market. They all come with new key characteristics – high value one-time therapies with long-term value and some even with a curative potential. This has profound implications on interactions of sponsors with patients on the one side and the whole ecosystem on the other side. This talk will give an oversight on new challenges and opportunities as well as an outlook to potential ways ahead.

  •  Cell and gene therapies
  • CAR-T cell therapies
  • Evolving patient engagement in one-time therapies

Karin BLUMER

Director Global Patient Engagement

Marta Garcia MANRIQUE

R&D. Chief Patient Officer

CASE STUDY / DAY 2

Patient Engagement on Clinical Research: Challenges and Opportunities

The value of incorporating patients’ insights on clinical development is now widely accepted, however, the incorporation of patient engagement in the development of new drugs is still very variable. The presentation will address this situation identifying possible reasons and possible solutions.

  • The value of patient engagement on medical research
  • The current situation of patient engagement
  • Challenges of PE in practice
  • New possibilities and examples

Excellent conference. Great discussions. The size of this conference allows for great dialogues.

Global Patient Centricity Director, Ipsen

STAY UPDATED FOR THE 2022 EDITION

Provide Us With Your Contact Details and Our Team Will Get Back to You With All the Updates Regarding the Upcoming Edition of This Event.